GlassScriptPhysician profile
Katherine E Thompson
NPI 1629555198
$10,308.55
in general payments reported to CMS, 2019-2025
27 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,786 · 2022: $1,856 · 2023: $1,953 · 2024: $2,275 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,089 · Consulting Fee: $400 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,088.89 |
| Consulting Fee | $400.00 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,282.72 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,250.31 | 2021-2025 | Wainua, Farxiga, Andexxa |
| Actelion Pharmaceuticals US, INC. | $1,175.55 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $882.35 | 2021-2025 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $807.76 | 2021-2025 | |
| Pfizer INC. | $760.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $717.97 | 2021-2025 | |
| Abbott Laboratories | $709.92 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate II, Lvas Implant Kit, Heartmate Touch |
| United Therapeutics Corporation | $662.35 | 2021-2025 | Remodulin, Orenitram, Remodulin |
| Alnylam Pharmaceuticals INC. | $636.58 | 2021-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $336.84 | 2023-2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $251.00 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.90 | 2021-2025 | Lifevest |
| Bridgebio Pharma, INC. | $142.49 | 2025 | Attruby |
| Astellas Pharma US INC | $95.27 | 2021-2024 | Cresemba |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $71.38 | 2024-2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $62.86 | 2023-2024 | |
| Novo Nordisk INC | $62.79 | 2025 | Wegovy |
| Abbvie INC. | $47.74 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $37.09 | 2022 | |
| Paragonix Technologies, INC. | $34.54 | 2024-2025 | Baroguard, Lungguard, Liverguard |
| Daiichi Sankyo INC. | $27.80 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $24.78 | 2022 | |
| Liquidia Technologies, INC. | $18.66 | 2025 | Yutrepia |
| Lilly USA, LLC | $14.44 | 2025 | Zepbound |
| Amgen INC. | $13.47 | 2025 | Repatha |
| Philips North America LLC | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.